<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39312156</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1559-0283</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Sep</Month><Day>23</Day></PubDate></JournalIssue><Title>Cell biochemistry and biophysics</Title><ISOAbbreviation>Cell Biochem Biophys</ISOAbbreviation></Journal><ArticleTitle>Understanding the Impact of SARS-CoV-2 on Lung Endothelial Cells: Brief Mechanisms Unveiled.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12013-024-01529-w</ELocationID><Abstract><AbstractText>As the world grapples with the coronavirus-19 (COVID) pandemic, more reports are coming in regarding Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in endotheliopathy. It is a vascular condition in which endothelial cell injury or damage inflicts anatomical and functional changes in the endothelium, significantly impacting the physiological process and function. Previously, it was assumed that SARS-CoV-2 infects respiratory epithelial cells via spike glycoproteins present on the surface of the virus. However, severe cases and different autopsy studies described the clandestine role of this virus in infecting endothelial cells other than epithelial cells. It was observed that SARS-CoV-2 targets the pulmonary and extrapulmonary systems to damage the microvasculature and affect respiratory functioning, resulting in the onset of endotheliopathy, thrombosis, inflammation, pulmonary edema, and fibrosis. Such deleterious events are the consequence of the hyperactive immune response initiated by the SARS-CoV-2 infection, leading to pulmonary and extrapulmonary complications. However, the molecular mechanism behind endotheliopathy and other complications caused by this virus is elusive and will be unraveled by covering recent literature in this mini-review.</AbstractText><CopyrightInformation>© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Fahad Hassan</ForeName><Initials>FH</Initials><AffiliationInfo><Affiliation>College of Pharmacy, Chosun University, Gwangju, 61452, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bang</LastName><ForeName>Jun Young</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>College of Pharmacy, Chosun University, Gwangju, 61452, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemical Engineering, Chosun University, Gwangju, 61452, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nam</LastName><ForeName>Yoon Seok</ForeName><Initials>YS</Initials><AffiliationInfo><Affiliation>College of Pharmacy, Chosun University, Gwangju, 61452, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hwang</LastName><ForeName>In Seo</ForeName><Initials>IS</Initials><AffiliationInfo><Affiliation>College of Pharmacy, Chosun University, Gwangju, 61452, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemical Engineering, Chosun University, Gwangju, 61452, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Dae Hong</ForeName><Initials>DH</Initials><AffiliationInfo><Affiliation>College of Pharmacy, Chosun University, Gwangju, 61452, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemical Engineering, Chosun University, Gwangju, 61452, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ki</LastName><ForeName>Minkyoung</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>College of Pharmacy, Chosun University, Gwangju, 61452, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salman</LastName><ForeName>Saad</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, CECOS University of IT &amp; Emerging Sciences, Peshawar, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Heon-Woo</ForeName><Initials>HW</Initials><AffiliationInfo><Affiliation>College of Pharmacy, Chosun University, Gwangju, 61452, Republic of Korea. hwlee@chosun.ac.kr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K209365001-2023</GrantID><Agency>Chosun University</Agency><Country /></Grant><Grant><GrantID>K209365001-2023</GrantID><Agency>Chosun University</Agency><Country /></Grant><Grant><GrantID>K209365001-2023</GrantID><Agency>Chosun University</Agency><Country /></Grant><Grant><GrantID>K209365001-2023</GrantID><Agency>Chosun University</Agency><Country /></Grant><Grant><GrantID>K209365001-2023</GrantID><Agency>Chosun University</Agency><Country /></Grant><Grant><GrantID>K209365001-2023</GrantID><Agency>Chosun University</Agency><Country /></Grant><Grant><GrantID>K209365001-2023</GrantID><Agency>Chosun University</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Biochem Biophys</MedlineTA><NlmUniqueID>9701934</NlmUniqueID><ISSNLinking>1085-9195</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Endothelial Cells</Keyword><Keyword MajorTopicYN="N">Endotheliopathy</Keyword><Keyword MajorTopicYN="N">Immune Response</Keyword><Keyword MajorTopicYN="N">Severe Acute Respiratory Syndrome Coronavirus 2</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>23</Day><Hour>12</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>23</Day><Hour>12</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>23</Day><Hour>11</Hour><Minute>22</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39312156</ArticleId><ArticleId IdType="doi">10.1007/s12013-024-01529-w</ArticleId><ArticleId IdType="pii">10.1007/s12013-024-01529-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Perico, L., Morigi, M., Pezzotta, A., Locatelli, M., Imberti, B., &amp; Corna, D., et al. (2023). SARS-CoV-2 spike protein induces lung endothelial cell dysfunction and thrombo-inflammation depending on the C3a/C3a receptor signalling. Scientific Reports, 13(1), 11392.</Citation><ArticleIdList><ArticleId IdType="pubmed">37452090</ArticleId><ArticleId IdType="pmc">10349115</ArticleId><ArticleId IdType="doi">10.1038/s41598-023-38382-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Islam, M. J., Islam, N. N., Alom, M. S., Kabir, M., &amp; Halim, M. A. (2023). A review on structural, non-structural, and accessory proteins of SARS-CoV-2: Highlighting drug target sites. Immunobiology, 228(1), 152302.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imbio.2022.152302</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah F. H., Lim K. H., Kim S. J. (2021). Bioinformatic analysis of antiviral medicinal compounds against Sars Cov-2 proteases. Kuwait Journal of Science. Special Issue, 1–12.</Citation></Reference><Reference><Citation>Salman, S., Shah, F. H., Idrees, J., Idrees, F., Velagala, S., Ali, J., &amp; Khan, A. A. (2020). Virtual screening of immunomodulatory medicinal compounds as promising anti-SARS-COV-2 inhibitors. Future Virology, 15(5), 267–275.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/fvl-2020-0079</ArticleId></ArticleIdList></Reference><Reference><Citation>Perico, L., Benigni, A. &amp; &amp; Remuzzi, G. (2023). SARS-CoV-2 and the spike protein in endotheliopathy. Trends in Microbiology, 32(1), 53–67.</Citation><ArticleIdList><ArticleId IdType="pubmed">37393180</ArticleId><ArticleId IdType="doi">10.1016/j.tim.2023.06.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Ackermann, M., Verleden, S. E., Kuehnel, M., Haverich, A., Welte, T., &amp; Laenger, F., et al. (2020). Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. New England Journal of Medicine, 383(2), 120–128.</Citation><ArticleIdList><ArticleId IdType="pubmed">32437596</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa2015432</ArticleId></ArticleIdList></Reference><Reference><Citation>Bussani, R., Schneider, E., Zentilin, L., Collesi, C., Ali, H., &amp; Braga, L., et al. (2020). Persistence of viral RNA, pneumocyte syncytia and thrombosis are hallmarks of advanced COVID-19 pathology. eBioMedicine, 61, 103104.</Citation><ArticleIdList><ArticleId IdType="pubmed">33158808</ArticleId><ArticleId IdType="pmc">7677597</ArticleId><ArticleId IdType="doi">10.1016/j.ebiom.2020.103104</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox, S. E., Akmatbekov, A., Harbert, J. L., Li, G., Quincy Brown, J., &amp; Vander Heide, R. S. (2020). Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans. The Lancet Respiratory Medicine, 8(7), 681–686.</Citation><ArticleIdList><ArticleId IdType="pubmed">32473124</ArticleId><ArticleId IdType="pmc">7255143</ArticleId><ArticleId IdType="doi">10.1016/S2213-2600(20)30243-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Rapkiewicz, A. V., Mai, X., Carsons, S. E., Pittaluga, S., Kleiner, D. E., &amp; Berger, J. S., et al. (2020). Megakaryocytes and platelet-fibrin thrombi characterize multi-organ thrombosis at autopsy in COVID-19: A case series. eClinicalMedicine, 24, 100434.</Citation><ArticleIdList><ArticleId IdType="pubmed">32766543</ArticleId><ArticleId IdType="pmc">7316051</ArticleId><ArticleId IdType="doi">10.1016/j.eclinm.2020.100434</ArticleId></ArticleIdList></Reference><Reference><Citation>Wichmann, D., Sperhake, J.-P., Lütgehetmann, M., Steurer, S., Edler, C., &amp; Heinemann, A., et al. (2020). Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study. Annals of internal medicine, 173(4), 268–277.</Citation><ArticleIdList><ArticleId IdType="pubmed">32374815</ArticleId><ArticleId IdType="doi">10.7326/M20-2003</ArticleId></ArticleIdList></Reference><Reference><Citation>Valdebenito, S., Bessis, S., Annane, D., Lorin de la Grandmaison, G., Cramer–Bordé, E., &amp; Prideaux, B., et al. (2021). COVID-19 lung pathogenesis in SARS-CoV-2 autopsy cases. Frontiers in immunology, 12, 735922.</Citation><ArticleIdList><ArticleId IdType="pubmed">34671353</ArticleId><ArticleId IdType="pmc">8521087</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2021.735922</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma, Z., Yang, K. Y., Huang, Y., &amp; Lui, K. O. (2022). Endothelial contribution to COVID-19: an update on mechanisms and therapeutic implications. Journal of Molecular and Cellular Cardiology, 164, 69–82.</Citation><ArticleIdList><ArticleId IdType="pubmed">34838588</ArticleId><ArticleId IdType="doi">10.1016/j.yjmcc.2021.11.010</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu, S.-w, Ilyas, I., &amp; Weng, J.-p (2023). Endothelial dysfunction in COVID-19: an overview of evidence, biomarkers, mechanisms and potential therapies. Acta Pharmacologica Sinica, 44(4), 695–709.</Citation><ArticleIdList><ArticleId IdType="pubmed">36253560</ArticleId><ArticleId IdType="doi">10.1038/s41401-022-00998-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Otifi, H. M., &amp; Adiga, B. K. (2022). Endothelial dysfunction in Covid-19 infection. The American journal of the medical sciences, 363(4), 281–287.</Citation><ArticleIdList><ArticleId IdType="pubmed">35093394</ArticleId><ArticleId IdType="pmc">8802031</ArticleId><ArticleId IdType="doi">10.1016/j.amjms.2021.12.010</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsikis, S. T., Hirsch, T. I., Fligor, S. C., Quigley, M., &amp; Puder, M. (2022). Targeting the lung endothelial niche to promote angiogenesis and regeneration: A review of applications. Frontiers in Molecular Biosciences, 9, 1093369.</Citation><ArticleIdList><ArticleId IdType="pubmed">36601582</ArticleId><ArticleId IdType="pmc">9807216</ArticleId><ArticleId IdType="doi">10.3389/fmolb.2022.1093369</ArticleId></ArticleIdList></Reference><Reference><Citation>Alice, H., Christophe, G., Joan, A. B., Peter, B., Jahar, B., &amp; Sunita, B., et al. (2018). Pulmonary vascular endothelium: the orchestra conductor in respiratory diseases. European Respiratory Journal, 51(4), 1700745.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.00745-2017</ArticleId></ArticleIdList></Reference><Reference><Citation>Millar, F. R., Summers, C., Griffiths, M. J., Toshner, M. R., &amp; Proudfoot, A. G. (2016). The pulmonary endothelium in acute respiratory distress syndrome: insights and therapeutic opportunities. Thorax, 71(5), 462–473.</Citation><ArticleIdList><ArticleId IdType="pubmed">26968969</ArticleId><ArticleId IdType="doi">10.1136/thoraxjnl-2015-207461</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, S., Zhang, Y., Guan, Z., Li, H., Ye, M., &amp; Chen, X., et al. (2020). SARS-CoV-2 triggers inflammatory responses and cell death through caspase-8 activation. Signal Transduction and Targeted Therapy, 5(1), 235.</Citation><ArticleIdList><ArticleId IdType="pubmed">33037188</ArticleId><ArticleId IdType="pmc">7545816</ArticleId><ArticleId IdType="doi">10.1038/s41392-020-00334-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, F., Han, K., Blair, R., Kenst, K., Qin, Z., &amp; Upcin, B., et al. (2021). SARS-CoV-2 Infects Endothelial Cells In Vivo and In Vitro. Frontiers in Cellular and Infection Microbiology, 11, 701278.</Citation><ArticleIdList><ArticleId IdType="pubmed">34307198</ArticleId><ArticleId IdType="pmc">8292147</ArticleId><ArticleId IdType="doi">10.3389/fcimb.2021.701278</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu, Y., Cheng, Y., &amp; Wu, Y. (2020). Understanding SARS-CoV-2-mediated inflammatory responses: from mechanisms to potential therapeutic tools. Virologica Sinica, 35(3), 266–271.</Citation><ArticleIdList><ArticleId IdType="pubmed">32125642</ArticleId><ArticleId IdType="pmc">7090474</ArticleId><ArticleId IdType="doi">10.1007/s12250-020-00207-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Pelle, M. C., Zaffina, I., Lucà, S., Forte, V., Trapanese, V., &amp; Melina, M., et al. (2022). Endothelial dysfunction in COVID-19: potential mechanisms and possible therapeutic options. Life, 12(10), 1605.</Citation><ArticleIdList><ArticleId IdType="pubmed">36295042</ArticleId><ArticleId IdType="pmc">9604693</ArticleId><ArticleId IdType="doi">10.3390/life12101605</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang, J. C. (2022). Molecular pathogenesis of endotheliopathy and endotheliopathic syndromes, leading to inflammation and microthrombosis, and various hemostatic clinical phenotypes based on “two-activation theory of the endothelium” and “two-path unifying theory” of hemostasis. Medicina, 58(9), 1311.</Citation><ArticleIdList><ArticleId IdType="pubmed">36143988</ArticleId><ArticleId IdType="pmc">9504959</ArticleId><ArticleId IdType="doi">10.3390/medicina58091311</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbosa, L. C., Gonçalves, T. L., de Araujo, L. P., Rosario, L. Vd. O., &amp; Ferrer, V. P. (2021). Endothelial cells and SARS-CoV-2: An intimate relationship. Vascular Pharmacology, 137, 106829.</Citation><ArticleIdList><ArticleId IdType="pubmed">33422689</ArticleId><ArticleId IdType="pmc">7834309</ArticleId><ArticleId IdType="doi">10.1016/j.vph.2021.106829</ArticleId></ArticleIdList></Reference><Reference><Citation>Klouda, T., Hao, Y., Kim, H., Kim, J., Olejnik, J., &amp; Hume, A. J., et al. (2022). Interferon-alpha or-beta facilitates SARS-CoV-2 pulmonary vascular infection by inducing ACE2. Angiogenesis, 25(2), 225–240. 1-16.</Citation><ArticleIdList><ArticleId IdType="pubmed">34714440</ArticleId><ArticleId IdType="doi">10.1007/s10456-021-09823-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Bayati, A., Kumar, R., Francis, V., &amp; McPherson, P. S. (2021). SARS-CoV-2 infects cells after viral entry via clathrin-mediated endocytosis. Journal of Biological Chemistry, 296, 100306.</Citation><ArticleIdList><ArticleId IdType="pubmed">33476648</ArticleId><ArticleId IdType="pmc">7816624</ArticleId><ArticleId IdType="doi">10.1016/j.jbc.2021.100306</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang, J., Wan, Y., Luo, C., Ye, G., Geng, Q., Auerbach, A., &amp; Li, F. (2020). Cell entry mechanisms of SARS-CoV-2. Proceedings of the National Academy of Sciences, 117(21), 11727–11734.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2003138117</ArticleId></ArticleIdList></Reference><Reference><Citation>Robles, J. P., Zamora, M., Adan-Castro, E., Siqueiros-Marquez, L., de la Escalera, G. M., &amp; Clapp, C. (2022). The spike protein of SARS-CoV-2 induces endothelial inflammation through integrin α5β1 and NF-κB signaling. Journal of Biological Chemistry, 298(3), 101695.</Citation><ArticleIdList><ArticleId IdType="pubmed">35143839</ArticleId><ArticleId IdType="pmc">8820157</ArticleId><ArticleId IdType="doi">10.1016/j.jbc.2022.101695</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin, Z., Liu, F., Blair, R., Wang, C., Yang, H., &amp; Mudd, J., et al. (2021). Endothelial cell infection and dysfunction, immune activation in severe COVID-19. Theranostics, 11(16), 8076.</Citation><ArticleIdList><ArticleId IdType="pubmed">34335981</ArticleId><ArticleId IdType="pmc">8315069</ArticleId><ArticleId IdType="doi">10.7150/thno.61810</ArticleId></ArticleIdList></Reference><Reference><Citation>Raghavan, S., Kenchappa, D. B., &amp; Leo, M. D. (2021). SARS-CoV-2 spike protein induces degradation of junctional proteins that maintain endothelial barrier integrity. Frontiers in cardiovascular medicine, 8, 687783.</Citation><ArticleIdList><ArticleId IdType="pubmed">34179146</ArticleId><ArticleId IdType="pmc">8225996</ArticleId><ArticleId IdType="doi">10.3389/fcvm.2021.687783</ArticleId></ArticleIdList></Reference><Reference><Citation>Avolio E., Carrabba M., Gu Y., Tsang C. T. W., Amulic B., Savitri E. R., et al., editors (2022). Intravascular administration of soluble SARS-CoV-2 Spike protein triggers non-infective heart and lung inflammation and vascular pericytes rarefaction in healthy mice. ESC Congress; 2022.</Citation></Reference><Reference><Citation>Zekri-Nechar, K., Zamorano-León, J. J., Reche, C., Giner, M., López-de-Andrés, A., &amp; Jiménez-García, R., et al. (2022). Spike Protein Subunits of SARS-CoV-2 Alter Mitochondrial Metabolism in Human Pulmonary Microvascular Endothelial Cells: Involvement of Factor Xa. Disease Markers, 2022, 1118195.</Citation><ArticleIdList><ArticleId IdType="pubmed">36438904</ArticleId><ArticleId IdType="pmc">9699787</ArticleId><ArticleId IdType="doi">10.1155/2022/1118195</ArticleId></ArticleIdList></Reference><Reference><Citation>Perico, L., Morigi, M., Galbusera, M., Pezzotta, A., Gastoldi, S., &amp; Imberti, B., et al. (2022). SARS-CoV-2 Spike Protein 1 Activates Microvascular Endothelial Cells and Complement System Leading to Platelet Aggregation. Frontiers in Immunology, 13, 827146.</Citation><ArticleIdList><ArticleId IdType="pubmed">35320941</ArticleId><ArticleId IdType="pmc">8936079</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2022.827146</ArticleId></ArticleIdList></Reference><Reference><Citation>Foote, C. A., Soares, R. N., Ramirez-Perez, F. I., Ghiarone, T., Aroor, A., &amp; Manrique-Acevedo, C., et al. (2022). Endothelial glycocalyx. Comprehensive Physiology, 12(4), 3781.</Citation><ArticleIdList><ArticleId IdType="pubmed">35997082</ArticleId><ArticleId IdType="pmc">10214841</ArticleId><ArticleId IdType="doi">10.1002/cphy.c210029</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki, A., Tomita, H., &amp; Okada, H. (2022). Form follows function: The endothelial glycocalyx. Translational Research, 247, 158–167.</Citation><ArticleIdList><ArticleId IdType="pubmed">35421613</ArticleId><ArticleId IdType="doi">10.1016/j.trsl.2022.03.014</ArticleId></ArticleIdList></Reference><Reference><Citation>Jedlicka, J., Becker, B. F., &amp; Chappell, D. (2020). Endothelial Glycocalyx. Critical Care Clinics, 36(2), 217–232.</Citation><ArticleIdList><ArticleId IdType="pubmed">32172810</ArticleId><ArticleId IdType="doi">10.1016/j.ccc.2019.12.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, H.-q., Li, J., Xuan, C.-l., &amp; Ma, H.-c. (2020). A review on the physiological and pathophysiological role of endothelial glycocalyx. Journal of Biochemical and Molecular Toxicology, 34(11), e22571.</Citation><ArticleIdList><ArticleId IdType="pubmed">32659867</ArticleId><ArticleId IdType="doi">10.1002/jbt.22571</ArticleId></ArticleIdList></Reference><Reference><Citation>Biering, S. B., Gomes de Sousa, F. T., Tjang, L. V., Pahmeier, F., Zhu, C., &amp; Ruan, R., et al. (2022). SARS-CoV-2 Spike triggers barrier dysfunction and vascular leak via integrins and TGF-β signaling. Nature Communications, 13(1), 7630.</Citation><ArticleIdList><ArticleId IdType="pubmed">36494335</ArticleId><ArticleId IdType="pmc">9734751</ArticleId><ArticleId IdType="doi">10.1038/s41467-022-34910-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Nader, D., &amp; Kerrigan, S. W. (2022). Molecular Cross-Talk between Integrins and Cadherins Leads to a Loss of Vascular Barrier Integrity during SARS-CoV-2 Infection. Viruses, 14(5), 891.</Citation><ArticleIdList><ArticleId IdType="pubmed">35632633</ArticleId><ArticleId IdType="pmc">9143673</ArticleId><ArticleId IdType="doi">10.3390/v14050891</ArticleId></ArticleIdList></Reference><Reference><Citation>Simons, P., Rinaldi, D. A., Bondu, V., Kell, A. M., Bradfute, S., Lidke, D. S., &amp; Buranda, T. (2021). Integrin activation is an essential component of SARS-CoV-2 infection. Scientific Reports, 11(1), 20398.</Citation><ArticleIdList><ArticleId IdType="pubmed">34650161</ArticleId><ArticleId IdType="pmc">8516859</ArticleId><ArticleId IdType="doi">10.1038/s41598-021-99893-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Bekassy, Z., Lopatko Fagerström, I., Bader, M., &amp; Karpman, D. (2022). Crosstalk between the renin–angiotensin, complement and kallikrein–kinin systems in inflammation. Nature Reviews Immunology, 22(7), 411–428.</Citation><ArticleIdList><ArticleId IdType="pubmed">34759348</ArticleId><ArticleId IdType="doi">10.1038/s41577-021-00634-8</ArticleId></ArticleIdList></Reference><Reference><Citation>de Carvalho, P. R., Sirois, P., &amp; Fernandes, P. D. (2021). The role of kallikrein-kinin and renin-angiotensin systems in COVID-19 infection. Peptides, 135, 170428.</Citation><ArticleIdList><ArticleId IdType="pubmed">33065209</ArticleId><ArticleId IdType="doi">10.1016/j.peptides.2020.170428</ArticleId></ArticleIdList></Reference><Reference><Citation>Martyniak, A., &amp; Tomasik, P. J. (2022). A new perspective on the renin-angiotensin system. Diagnostics, 13(1), 16.</Citation><ArticleIdList><ArticleId IdType="pubmed">36611307</ArticleId><ArticleId IdType="pmc">9818283</ArticleId><ArticleId IdType="doi">10.3390/diagnostics13010016</ArticleId></ArticleIdList></Reference><Reference><Citation>Marceau, F. (2023). Drugs of the Kallikrein–Kinin System: An Overview. Drugs and Drug Candidates, 2(3), 538–553.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ddc2030028</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei, Y., Zhang, J., Schiavon, C. R., He, M., Chen, L., &amp; Shen, H., et al. (2021). SARS-CoV-2 Spike Protein Impairs Endothelial Function via Downregulation of ACE 2. Circulation Research, 128(9), 1323–1326.</Citation><ArticleIdList><ArticleId IdType="pubmed">33784827</ArticleId><ArticleId IdType="pmc">8091897</ArticleId><ArticleId IdType="doi">10.1161/CIRCRESAHA.121.318902</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbieri, S. S., Cattani, F., Sandrini, L., Grillo, M. M., Amendola, A., &amp; Valente, C., et al. (2023). Relevance of Spike/Estrogen Receptor-α interaction for endothelial-based coagulopathy induced by SARS-CoV-2. Signal Transduction and Targeted Therapy, 8(1), 203.</Citation><ArticleIdList><ArticleId IdType="pubmed">37208343</ArticleId><ArticleId IdType="pmc">10196308</ArticleId><ArticleId IdType="doi">10.1038/s41392-023-01488-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Aiello, S., Gastoldi, S., Galbusera, M., Ruggenenti, P., Portalupi, V., &amp; Rota, S., et al. (2022). C5a and C5aR1 are key drivers of microvascular platelet aggregation in clinical entities spanning from aHUS to COVID-19. Blood Advances, 6(3), 866–881.</Citation><ArticleIdList><ArticleId IdType="pubmed">34852172</ArticleId><ArticleId IdType="pmc">8945302</ArticleId><ArticleId IdType="doi">10.1182/bloodadvances.2021005246</ArticleId></ArticleIdList></Reference><Reference><Citation>Agrati, C., Sacchi, A., Tartaglia, E., Vergori, A., Gagliardini, R., Scarabello, A., &amp; Bibas, M. (2021). The Role of P-Selectin in COVID-19 Coagulopathy: An Updated Review. International Journal of Molecular Sciences [Internet], 22(15), 7942.</Citation><ArticleIdList><ArticleId IdType="pubmed">34360707</ArticleId><ArticleId IdType="doi">10.3390/ijms22157942</ArticleId></ArticleIdList></Reference><Reference><Citation>Niethamer, T. K., Stabler, C. T., Leach, J. P., Zepp, J. A., Morley, M. P., &amp; Babu, A., et al. (2020). Defining the role of pulmonary endothelial cell heterogeneity in the response to acute lung injury. Elife, 9, e53072.</Citation><ArticleIdList><ArticleId IdType="pubmed">32091393</ArticleId><ArticleId IdType="pmc">7176435</ArticleId><ArticleId IdType="doi">10.7554/eLife.53072</ArticleId></ArticleIdList></Reference><Reference><Citation>Huertas, A., Montani, D., Savale, L., Pichon, J., Tu, L., &amp; Parent, F., et al. (2020). Endothelial cell dysfunction: a major player in SARS-CoV-2 infection (COVID-19)? Eur Respiratory Soc, 56(1), 2001634.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.01634-2020</ArticleId></ArticleIdList></Reference><Reference><Citation>Lui, K. O., Ma, Z., &amp; Dimmeler, S. (2023). SARS-CoV-2 induced vascular endothelial dysfunction: direct or indirect effects? Cardiovascular Research, 120(1), 34–43.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cvr/cvad191</ArticleId></ArticleIdList></Reference><Reference><Citation>Gavriatopoulou, M., Korompoki, E., Fotiou, D., Ntanasis-Stathopoulos, I., Psaltopoulou, T., &amp; Kastritis, E., et al. (2020). Organ-specific manifestations of COVID-19 infection. Clinical and experimental medicine, 20, 493–506.</Citation><ArticleIdList><ArticleId IdType="pubmed">32720223</ArticleId><ArticleId IdType="pmc">7383117</ArticleId><ArticleId IdType="doi">10.1007/s10238-020-00648-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Giordo, R., Paliogiannis, P., Mangoni, A. A., &amp; Pintus, G. (2021). SARS-CoV-2 and endothelial cell interaction in COVID-19: molecular perspectives. Vascular Biology, 3(1), R15–R23.</Citation><ArticleIdList><ArticleId IdType="pubmed">33659858</ArticleId><ArticleId IdType="pmc">7923034</ArticleId><ArticleId IdType="doi">10.1530/VB-20-0017</ArticleId></ArticleIdList></Reference><Reference><Citation>Six, I., Guillaume, N., Jacob, V., Mentaverri, R., Kamel, S., Boullier, A., &amp; Slama, M. (2022). The Endothelium and COVID-19: An Increasingly Clear Link Brief Title: Endotheliopathy in COVID-19. International Journal of Molecular Sciences. 23(11), 6196.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>